GlassScriptPhysician profile
Staci Nicole Hicks
NPI 1811566524
$7,193.64
in general payments reported to CMS, 2019-2025
56 companies · $2,093 in 2025
The $2,093 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $901 · 2023: $2,151 · 2024: $1,894 · 2025: $2,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,931 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,930.62 |
| Education | $206.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $764.80 | 2022-2025 | |
| Abbvie INC. | $443.72 | 2023-2025 | |
| Incyte Corporation | $408.55 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $405.14 | 2022-2025 | Imfinzi, Lynparza, Calquence |
| Pfizer INC. | $379.24 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $355.27 | 2022-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $349.41 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $333.60 | 2023-2025 | Ninlaro, Fruzaqla, Iclusig |
| Daiichi Sankyo INC. | $292.55 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Alexion Pharmaceuticals, INC. | $234.49 | 2023-2025 | Ultomiris, Soliris |
| Galt Pharmaceuticals, LLC | $226.98 | 2023 | Orphengesic Forte, Oravig |
| Lilly USA, LLC | $188.55 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $180.94 | 2022-2025 | Reblozyl, Pomalyst |
| Sobi, INC | $149.20 | 2024-2025 | |
| Janssen Biotech, INC. | $143.24 | 2022-2025 | Rybrevant, Darzalex, Talvey |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $136.09 | 2025 | Brukinsa, Tevimbra |
| Exelixis INC. | $125.38 | 2023-2024 | Cabometyx |
| Array Biopharma INC | $119.65 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $115.46 | 2022-2025 | |
| Genzyme Corporation | $114.59 | 2021-2025 | |
| Amgen INC. | $112.82 | 2022-2023 | Repatha |
| Glaxosmithkline, LLC. | $103.16 | 2023-2025 | Jemperli, Zejula |
| Regeneron Healthcare Solutions, INC. | $101.11 | 2021-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $82.03 | 2021-2023 | Imbruvica |
| Aveo Pharmaceuticals, INC. | $80.70 | 2022-2025 | Fotivda |
| Astellas Pharma US INC | $76.43 | 2022-2025 | Xtandi, Padcev |
| Blueprint Medicines Corporation | $75.57 | 2022-2024 | Ayvakit |
| Stemline Therapeutics INC. | $72.80 | 2024-2025 | Orserdu |
| Genentech USA, INC. | $65.84 | 2024-2025 | Polivy, Tecentriq, Lunsumio |
| Sumitomo Pharma America, INC. | $60.69 | 2023-2025 | Orgovyx |
| Coherus Oncology, INC. | $57.37 | 2023-2025 | Udenyca |
| Seagen INC. | $52.48 | 2022-2023 | Padcev |
| Deciphera Pharmaceuticals INC. | $52.16 | 2023-2025 | Qinlock, Romvimza |
| Jazz Pharmaceuticals INC. | $46.70 | 2022-2023 | |
| Apellis Pharmaceuticals, INC. | $45.22 | 2023 | Empaveli |
| Progenics Pharmaceuticals, INC. | $44.38 | 2022-2023 | Pylarify |
| Servier Pharmaceuticals LLC | $44.10 | 2024-2025 | |
| Taiho Oncology, INC. | $41.74 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $40.74 | 2022 | |
| Puma Biotechnology, INC. | $40.69 | 2024 | |
| Eisai INC. | $40.38 | 2022-2023 | |
| Mirati Therapeutics, INC. | $38.22 | 2023-2024 | Krazati |
| Acrotech Biopharma INC. | $34.94 | 2021-2023 | Beleodaq |
| Agios Pharmaceuticals, INC. | $34.30 | 2025 | Pyrukynd |
| Adc Therapeutics America, INC. | $34.27 | 2022 | |
| Csl Behring | $31.49 | 2023 | Hizentra |
| Kite Pharma, INC. | $28.97 | 2023 | Yescarta |
| Sun Pharmaceutical Industries INC. | $28.08 | 2023 | Yonsa, Odomzo |
| Pharmaessentia USA Corporation | $26.74 | 2024 | Besremi |
| Adaptive Biotechnologies Corporation | $22.61 | 2025 | Clonoseq |
| Immunocore Limited | $22.56 | 2025 | Kimmtrak |
| Fennec Pharmaceuticals, INC. | $21.95 | 2025 | Fyarro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.76 | 2025 | |
| Sanofi-Aventis U.S. LLC | $18.68 | 2021 | |
| Shield Therapeutics INC | $14.79 | 2022 | |
| Rigel Pharmaceuticals, INC. | $13.32 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staci Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.